MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
As part of Protisvalor, the research transfer subsidiary of Aix-Marseille University, I have accompanied researchers from the University for nearly 4 years, first to identify European funding opportunities to meet their needs and then to help them develop proposals for submission to the European Commission. As an immunologist, I have participated in all stages of the innovation chain of Marseille Immunopôle, from research to industry and technology transfer. I have always followed R&D projects with particular interest on collaborative projects focused on immunology, involving both scientists, clinicians and industrials.
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players. MI will make us more visible and efficient. Together, we have the unique opportunity to make Marseille metropolis a global hub for fundamental and applied immunology and a capital for immunotherapy R&D. Being involved in this very ambitious project is a privilege and a real responsibility!#ecosystème #industrie
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.
AMU, IPC, AP-HM, Inserm
We have developed a library of human tumors xenografted on immunodepressed mice
Michel IOVANNA JUAN
AMU, IPC, CRCM
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.